Published • loading... • Updated
Investment Analysts’ Recent Ratings Changes for Ultragenyx Pharmaceutical (RARE)
Summary by thecerbatgem.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Investment Analysts’ Recent Ratings Changes for Ultragenyx Pharmaceutical (RARE)
A number of research firms have changed their ratings and price targets for Ultragenyx Pharmaceutical (NASDAQ: RARE): 10/6/2026 – Ultragenyx Pharmaceutical had its “sell (d-)” rating reaffirmed by Weiss Ratings. 9/23/2026 – Ultragenyx Pharmaceutical was upgraded by William Blair to “hold”. 9/21/2026 – Ultragenyx Pharmaceutical had its price target raised by Barclays PLC from $32.00 […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
